BioSpace News Archive

Acasti Pharma Inc. announces the Company has commenced a formal process to explore and evaluate strategic alternatives to enhance shareholder value.

Freeline Therapeutics Holdings plc announced that Theresa Heggie, Chief Executive Officer, will present at Chardan’s 4th Annual Genetic Medicines Conference at the revised time of 3.45 pm EDT on 6 October.

Boehringer Ingelheim has acquired an equity stake in New Ruipeng Group (NRP Group) which operates digital and clinical pet services across China

BHR Pharmaceuticals Ltd and SphingoTec GmbH announced that they have signed a distribution agreement for the commercialization of SphingoTec’s portfolio of diagnostics solutions in acute and critical care in UK and Ireland.

Immunic, Inc., a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, announced participation in the following scientific conferences in October:

Study adds further validation that Annovis’ lead compound is the only drug to improve axonal transport, the information highway of the nerve cell

Renowned surgeon, clinician, and researcher to advance work to combine novel immuno-oncology therapies with regional drug delivery to improve outcomes in metastatic liver and pancreatic tumors

Mereo BioPharma Group plc, “Mereo” or “the Company”, a clinical stage biopharmaceutical company focused on oncology and rare diseases, announces unaudited interim financial results for the six months ended June 30, 2020 and provides a corporate update.

Vor Biopharma , an oncology company pioneering engineered hematopoietic stem cells (eHSCs) for the treatment of cancer, and Arbor Biotechnologies, an early-stage life sciences company, today announced an agreement to use Arbor’s gene editing technologies to engineer hematopoietic stem cells, towards the goal of developing therapies for the treatment of blood cancers, such as acute myeloid leukemia. “At Vor, we ar

Inversago Pharma Inc. (“the Company” or “Inversago”), the peripheral CB1 blockade company, today announced it has initiated a Phase 1 clinical trial of INV-101, the Company’s peripherally-acting CB1 blocker, which is being developed for the treatment of Prader-Willi syndrome (PWS) and non-alcoholic steatohepatitis (NASH). The trial will evaluate the safety, tolerability and pharmacokinetics of INV-101. Recruitment is ongo